In particular, those compounds or their metabolites could affect patients who already suffer from compromised drug metabolism and clearance or from impairments in proper CASQ function, such as those afflicted with catecholaminergic polymorphic ventricular tachycardia (CPVT) or malignant hyperthermia (MH) [9,18]. This evidence concerns the gene CASQ1 and catecholaminergic polymorphic ventricular tachycardia.